Implicaciones clínicas del uso de la triple terapia en combinación de dosis fija en EPOC: del ensayo al paciente

Lopez-Campos, 2017, Triple therapy vs triple therapy in COPD, Arch Bronconeumol., 53, 419, 10.1016/j.arbres.2017.01.020 Abad-Arranz, 2019, Quantification of inaccurate diagnosis of COPD in primary care medicine: An analysis of the COACH clinical audit, Int J Chron Obstruct Pulmon Dis., 14, 1187, 10.2147/COPD.S199322 Calle Rubio, 2018, Medical care according to risk level and adaptation to Spanish COPD guidelines (Gesepoc): The Epoconsul Study, Arch Bronconeumol., 54, 270, 10.1016/j.arbres.2017.11.015 Lopez-Campos, 2018, Determinants of medical prescriptions for COPD care: An analysis of the EPOCONSUL clinical audit, Int J Chron Obstruct Pulmon Dis., 13, 2279, 10.2147/COPD.S160842 Vestbo, 2019, Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population, Int J Chron Obstruct Pulmon Dis., 14, 853, 10.2147/COPD.S189585 Mantero, 2018, Management of severe COPD exacerbations: Focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide, Int J Chron Obstruct Pulmon Dis., 13, 2319, 10.2147/COPD.S147484 Singh, 2016, Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial, Lancet., 388, 963, 10.1016/S0140-6736(16)31354-X Vestbo, 2017, Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial, Lancet., 389, 1919, 10.1016/S0140-6736(17)30188-5 Papi, 2018, Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial, Lancet., 391, 1076, 10.1016/S0140-6736(18)30206-X Molino, 2018, Patient considerations in the treatment of COPD: Focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol, Patient Prefer Adherence., 12, 993, 10.2147/PPA.S152179 Lipson, 2017, FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med., 196, 438, 10.1164/rccm.201703-0449OC Bremner, 2018, Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study, Respir Res., 19, 19, 10.1186/s12931-018-0724-0 Lipson, 2018, Once-daily single-inhaler triple versus dual therapy in patients with COPD, N Engl J Med., 378, 1671, 10.1056/NEJMoa1713901 Ferguson, 2018, Lancet Respir Med., 6, 747, 10.1016/S2213-2600(18)30327-8 Ambery, 2019, Open-label crossover study to determine the pharmacokinetics of fluticasone furoate and batefenterol when administered alone, in combination, or concurrently, Clin Pharmacol Drug Dev., 8, 188, 10.1002/cpdd.603 Singh, 2017, Triple therapy in COPD: New evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide, Int J Chron Obstruct Pulmon Dis., 12, 2917, 10.2147/COPD.S146822 Lai, 2019, The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized controlled trials, Int J Chron Obstruct Pulmon Dis., 14, 1539, 10.2147/COPD.S200846 Van der Palen, 2018, A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD, Int J Chron Obstruct Pulmon Dis., 13, 2515, 10.2147/COPD.S169060 Yu, 2011, Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: Multiple versus single long-acting maintenance inhalers, J Med Econ., 14, 486, 10.3111/13696998.2011.594123 Lopez-Campos, 2019, Status of and strategies for improving adherence to COPD treatment, Int J Chron Obstruct Pulmon Dis., 14, 1503, 10.2147/COPD.S170848 Feldman, 2017, Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: A randomized study, Adv Ther., 34, 2518, 10.1007/s12325-017-0626-4 Donohue, 2016, Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials, Respir Med., 112, 65, 10.1016/j.rmed.2016.01.001 Lopez-Campos, 2016, Determinants for changing the treatment of COPD: A regression analysis from a clinical audit, Int J Chron Obstruct Pulmon Dis., 11, 1171, 10.2147/COPD.S103614 Pablos-Mendez, 1998, Run-in periods in randomized trials: implications for the application of results in clinical practice, JAMA., 279, 222, 10.1001/jama.279.3.222 Laursen, 2019, Randomized clinical trials with run-in periods: frequency, characteristics and reporting, Clin Epidemiol., 11, 169, 10.2147/CLEP.S188752 Suissa, 2018, Making sense of triple inhaled therapy for COPD, N Engl J Med., 378, 1723, 10.1056/NEJMe1716802 Zheng, 2018, Triple therapy in the management of chronic obstructive pulmonary disease: Systematic review and meta-analysis, BMJ., 363 Cazzola, 2018, Triple therapy versus single dual long-acting bronchodilator therapy in COPD: A systematic review meta-analysis, Eur Respir J., 52, 1801586, 10.1183/13993003.01586-2018 Calzetta, 2019, Adding a LAMA to ICS/LABA therapy: A meta-analysis of triple combination therapy in COPD, Chest., 155, 758, 10.1016/j.chest.2018.12.016 Vanfleteren, 2018, Triple therapy (ICS/LABA/LAMA) in COPD: Time for a reappraisal, Int J Chron Obstruct Pulmon Dis., 13, 3971, 10.2147/COPD.S185975 Zayed, 2019, Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials, Clin Respir J., 13, 413, 10.1111/crj.13026